RxDoctor Payments DataLook up a doctor →

Louis Haenel, DO

Endocrinology, Diabetes & Metabolism · Charleston, SCNPI 1669412995

Payments from drug & device makers

$376,897in general payments, 2019–2025

Across 1,051 payments — averaging $358.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$211K
  • Lilly USA, LLC$146K
  • AstraZeneca$7K
  • Amgen$3K
  • Abbott$2K
  • Medtronic$1K
  • plus $6K from 46 others

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novo Nordisk240$211,214
Lilly USA, LLC285$146,061
AstraZeneca(2 entities)41$6,503
Amgen(2 entities)58$3,492
Abbott65$1,798
Medtronic(2 entities)70$1,356
Insulet Corporation37$967
Sanofi-aventis U.S. LLC18$528
Boehringer Ingelheim27$470
Xeris Pharmaceuticals, Inc.21$426
AbbVie20$411
Cequr Corporation4$372
Mannkind Corporation17$322
Bayer12$232
Amneal Pharmaceuticals LLC10$223
IBSA Pharma Inc.12$206
Corcept Therapeutics11$187
Ultragenyx Pharmaceutical Inc.5$185
Ascendis Pharma Endocrinology Inc11$172
Esperion Therapeutics, Inc.4$161
Valeritas, Inc.14$149
Ascensia Diabetes Care US Inc.6$142
Dexcom, Inc.4$135
Radius Health, Inc.5$103
Amarin Pharma, Inc.6$100
Chiasma, Inc.1$97
Tandem Diabetes Care, Inc.4$89
OPKO Pharmaceuticals, LLC4$89
Madrigal Pharmaceuticals3$72
Takeda Pharmaceuticals U.S.A., Inc.4$67
Chiesi USA, Inc.2$51
Merck4$49
Sequel Med Tech, LLC2$40
Johnson & Johnson3$39
Zealand Pharma US, Inc.2$38
Clarus Therapeutics Inc.2$37
Eisai Inc.1$30
Pfizer1$27
Intuity Medical Inc1$26
Sumitomo Pharma America, Inc.1$25
Endo Pharmaceuticals Inc.2$25
Novartis1$24
Scynexis, Inc.1$22
Antares Pharma, Inc.1$18
Astellas Pharma US Inc1$17
Shire North American Group Inc1$17
Neurocrine Biosciences, Inc.1$16
Halozyme Inc1$16
Lifescan, Inc.1$15
Vistapharm, Inc.1$12
Therapeuticsmd, Inc.1$12
Recordati_rare_diseases_inc.1$11

How this compares

$376,897 in reported general payments places this provider in the 90th percentile of 99 endocrinology, diabetes & metabolism providers in South Carolina.

See all endocrinology, diabetes & metabolism providers in South Carolina →

Medicare billing

Part B allowed, 2024
$159,325
Medicare patients
756
Services billed
1,560

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other endocrinology, diabetes & metabolism in Charleston

See the full list for South Carolina →

Where these figures come from

Is this you, or does something look wrong? →